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Background: Stage shift is widely considered a major determinant of the survival benefit conferred by breast
cancer screening. However, factors and mechanisms underlying such a prognostic advantage need further
clarification. We sought to compare the molecular characteristics of screen detected vs. symptomatic breast cancers
and assess whether differences in tumour biology might translate into survival benefit.
Methods: In a clinical series of 448 women with operable breast cancer, the Kaplan-Meier method and the log-rank
test were used to estimate the likelihood of cancer recurrence and death. The Cox proportional hazard model was
used for the multivariate analyses including mode of detection, age at diagnosis, tumour size, and lymph node
status. These same models were applied to subgroups defined by molecular subtypes.
Results: Screen detected breast cancers tended to show more favourable clinicopathological features and
survival outcomes compared to symptomatic cancers. The luminal A subtype was more common in women
with mammography detected tumours than in symptomatic patients (68.5 vs. 59.0%, p=0.04). Data analysis
across categories of molecular subtypes revealed significantly longer disease free and overall survival for
screen detected cancers with a luminal A subtype only (p=0.01 and 0.02, respectively). For women with a
luminal A subtype, the independent prognostic role of mode of detection on recurrence was confirmed in
Cox proportional hazard models (p=0.03). An independent role of modality of detection on survival was also
suggested (p=0.05).
Conclusions: Molecular subtypes did not substantially explain the differences in survival outcomes between
screened and symptomatic patients. However, our results suggest that molecular profiles might play a role in
interpreting such differences at least partially.
Further studies are warranted to reinterpret the efficacy of screening programmes in the light of tumour
biology.
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Consistent evidence from randomized controlled trials
of mammography in breast cancer screening demon-
strates a 20-35% reduction in mortality from the disease
[1-3]. On this basis, the Council of Europe recommends
population-based organized mammographic screenings
for women aged 50–69 years and claims that screening
programmes fulfil the European guidelines [1,2].
In Italy, as well as in most European countries, differ-
ent modalities of breast cancer screening coexist. The
Italian Ministry of Health supports the activation and
monitoring of organized breast cancer screening pro-
grammes. Asymptomatic women in the aforementioned
age range are individually identified and invited to at-
tend mammography screenings. Key issues such as eligi-
bility criteria, quality assurance, follow up of positive
results and programme evaluation are centrally regulated
and comply with national and international guidelines
[1,2]. Conversely, in opportunistic screenings, attend-
ance depends on the individuals decision or on the
recommendations given by health care providers. The
decentralized nature and lack of systematic reports on
activities and outcomes represent further distinctive
features [3,4].
Independently on whether organized or opportunistic,
breast cancer screening seems to impact cancer progno-
sis. Screening detected breast cancer cases tend to show
a more favorable prognosis compared to cancers clini-
cally detected. This has been partly ascribed to differ-
ences in tumour characteristics at diagnosis (e.g. tumour
stage and grade, axillary lymph node involvement). How-
ever, the persistence of a survival benefit after adjusting
for such characteristics suggests an independent role of
mode of breast cancer detection on patient prognosis
[4-9]. Factors and mechanisms underlying such a prog-
nostic advantage have not been fully elucidated yet.
In recent years, microarrays have allowed the identifica-
tion and characterization of distinct breast cancer sub-
types, namely, luminal A, luminal B, HER2 overexpressing
and triple negative tumours. The molecular heterogeneity
reflects alterations in cell biology and is associated with
significant differences in clinical outcomes [8,10].
Immunohistochemical techniques have contributed
details to the characterization of breast cancer subtypes.
Luminal A and luminal B breast cancers express the
oestrogen receptor (ER) and are also frequently progester-
one receptor (PR) positive. HER2 expression is described
in the HER2-overexpressing and luminal B subtypes,
whereas triple-negative breast cancers are defined by lack
of ER, PR and ERBB2 amplification [11-13].
We have previously addressed mode of breast cancer
detection in relation to diagnostic delay [8]. In the
present study, we sought to compare the molecular
characteristics of screen detected vs. symptomatic breastcancers and to assess whether differences in tumour
biology might translate into survival benefit.
Methods
Study participants
We conducted the present analysis on data derived from
a clinical series of 448 women diagnosed with incident,
histologically-confirmed breast cancer at the G. Pascale
National Cancer Institute of Naples, between January
2004 and June 2006. Detailed eligibility criteria were
reported elsewhere [14]. In brief, breast cancer patients
were included if aged ≥18 years and tumour samples
were available for molecular and immunohistochemical
characterization.
Data on pathologic features (e.g. tumour size and
grade at diagnosis), administered therapy, and survival
outcomes were gathered from our patient and pathology
databases. A validated, semi-structured questionnaire
was administered in face-to-face interviews to collect data
on demographics and mode of breast cancer detection.
Tumours were considered screen detected if suspicious
findings were first detected by breast imaging within the
routine national screening program or by opportunistic
screening without any symptoms. Conversely, in patients
with symptomatic tumours, breast imaging was performed
in the absence of screening and exclusively following self
breast examination or examination by an experienced
health care provider revealing symptoms related to breast
cancer, e.g. palpable lumps, changes in the skin over the
breast, changes in the shape and/or size of the breast.
In asymptomatic women aged 50 years and older, par-
ticipation in the national screening program was assessed
throughout a specifically tailored question on whether
they had undergone mammography following an invita-
tion letter from the local authority.Immunohistochemistry
Antigen expression was evaluated by an experienced
pathologist using light microscopy. The observer was
unaware of the clinical outcome. For each sample, at
least five fields (inside the tumour and in the area exhi-
biting tumour invasion) and >500 cells were analyzed.
Using a semiquantitative scoring system, the intensity,
extent and subcellular distribution of ER, PR, c-erb B2,
Ki67, CK 5/6, CK 14 and CK8/18 were evaluated.
The cutoff used to distinguish “positive” from “nega-
tive” cases was ≥ 1% ER/PR positive tumour cells. Immu-
nohistochemical analyses of HER2 expression describe the
intensity and staining pattern of tumour cells. Only
membrane staining intensity and pattern were evalu-
ated using the 0 to 3+ score as illustrated in the
HercepTest kit scoring guidelines. The FDA-recognized
test, the Herceptest™ (DAKO), describes four categories: no
Table 1 Descriptive characteristics of the study
participants by mode of breast cancer detection
MODE OF DETECTION
Descriptive Characteristics SYMPTOMATIC SCREEN
DETECTED
P-VALUE
No. % No. %
TOTAL 334 74.5 114 25.5
Age at diagnosis (years) <.0001
<40 47 14.1 3 2.6
40–49 78 23.4 28 24.6
50–69 150 44.9 77 67.5
≥70 59 17.7 6 5.3
Education (years) .06
<7 144 43.9 36 31.6
7–11 74 22.6 30 26.3
≥12 110 33.5 48 42.1
Marital status .006
Married/living as married 236 71.1 95 84.1
Not married 96 28.9 18 15.9
Menopausal status .06
Premenopausal 93 27.8 20 17.5
Perimenopausal 19 5.7 10 8.8
Postmenopausal 222 66.5 84 73.7
Body mass index .24
<25 132 41.4 48 44.9
25–29 105 32.9 40 37.4
≥30 82 25.7 19 17.8
Family History .51
None 232 69.5 73 64.0
FDR (≥1) 54 16.2 18 15.8
SDR (≥1) 41 12.3 19 16.7
FDR+SDR 7 2.1 4 3.5
Abbreviations: BC, breast cancer; FDR, first-degree relative; SDR, second-degree
relative.
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cells (0); weak staining in part of the membrane in more than
10% of the tumour cells (1+); complete staining of the mem-
brane with weak or moderate intensity in more than 10% of
the neoplastic cells (2+); and strong staining in more than
10% (3+). Scores of 0 or 1+ were considered negative for
HER2 expression, 2+ was uncertain, and 3+ was positive.
Cases 2 + undergo FISH analysis.
The proliferative index Ki67 was defined as the per-
centage of immunoreactive tumour cells out of the total
number of cells. The percentage of positive cells per case
was scored according to 2 different groups: group 1:
<15% (low proliferative activity); group 2: >15% (high
proliferative activity).
CKs stains were considered positive if any (weak or
strong) cytoplasmic and/or membranous invasive carci-
noma cell staining was observed.
Molecular subtype classification
Breast cancers were classified into five molecular sub-
types based on the expression of ER, PR, HER2, and
basal cytokeratins as follows: luminal A tumours (ER+
or PR+, and HER2-), luminal B tumours (ER+ or PR+,
and HER2+), non-luminal HER2+ tumours (ER-, PR-,
and HER2+), triple negative with expression of core
basal markers (ER-, PR-, HER2-, and CK5/6+ and/or
CK14+ and CK8/18-) and triple negative without expres-
sion of core basal markers (ER-, PR-, HER2-, and CK5/6-
and/or CK14- and CK8/18+).
Statistical analyses
Frequency tables were analyzed using the Chi-Square
test. The date of last follow-up for relapse-free or living
patients was 31-12-2010. Time from diagnosis to relapse
was recorded; time from diagnosis to development of
metastatic disease or death was then calculated and sur-
vival was compared by mode of cancer detection.
Estimation of the likelihood events for locoregional,
distant failure and overall survival (OS) were calculated
according to the Kaplan-Meier method. Statistical dif-
ferences between curves were calculated using log-rank
test [15,16].
The Cox proportional hazard model was used to test
the effect of several variables on survival outcomes in
multivariate analyses [17]. Mode of breast cancer detec-
tion, age at cancer diagnosis, tumour size, number of posi-
tive lymph nodes and, when analyzing the overall sample,
molecular subtypes were included as covariates. The same
models were applied to subgroups defined by molecular
subtypes. In addition, regression models were used to test
the interaction between mode of breast cancer detection
and each molecular subtype. A p value of <0.05 was con-
sidered significant. Statistical analysis was performed using
SPSS (version 16; SPSS, Inc., Chicago, IL).Results
In Table 1, patient characteristics are reported by mode
of breast cancer detection. Of these women, 334 (74.5%)
had symptomatic tumours and 114 (25.5%) had screen
detected tumours. In the screen detected group, only
three women among those aged 50 years and older
(3.61%) reported having undergone a mammography
after receiving an invitation letter from the local health
authority. Median follow-up for the overall sample was
61.8 months (range 4–83 months). Women who were
symptomatic at diagnosis were more commonly younger,
with the proportion of patients aged ≤ 49 years being
significantly higher compared to women in the mam-
mography group (37.5% vs. 27.2%, p<0.0001). Patients
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unmarried cases (28.9% vs. 15.9%, p=0.006).
Table 2 summarizes the baseline clinical, pathological
and immunohistochemical characteristics, along with
the administered treatment and outcomes of interest by
mode of breast cancer detection. Screen detected can-
cers were smaller, more likely to be node-negative, and
better differentiated than symptomatic ones (80.8 vs.
51.7%, p<0.0001; 70.2 vs. 52.8%, p=0.01 and 18.5 vs.
7.2%, p<0.0001, respectively).
A significantly higher proportion of cases expressed
PgR and showed a Ki-67 ≤20% among screen detected
cancers compared with symptomatic tumours (78.1% vs.
68%, p=0.04 and 57.1% vs. 44.1%, p=0.02, respectively).
Triple negative cancers were more common among the
self-detected cases than among the mammography ones
(10.2 vs. 1.7%, p= 0.006).
For women in the screen detected category, the surgi-
cal approach tended to be more conservative and
chemotherapy, either alone or combined to radiotherapy,
was less frequently administered compared to women
who were symptomatic at diagnosis (88.0 vs. 74.7%,
p=0.005; 7.3% vs. 10.9% and 45.5% vs. 56.2%, p=0.04,
respectively). A significantly higher percentage of women
with symptomatic cancer died from the disease during the
follow up compared to patients whose cancer was screen
detected (16.6 vs. 7.0%, p<0.0001). Patients alive at the last
follow up were more commonly free from the disease if
their cancer had been screen detected (88.5% vs. 71.0%,
p<0.0001). Loco-regional and distant recurrence were
more likely to occur in patients with a symptomatic can-
cer than in patients with a screen detected cancer (23.5 vs.
8.8% and 5.6 vs. 2.7%, respectively, p<0.001).
In univariate analyses, mode of breast cancer detection
was an independent predictor of both recurrence and
survival (HR: 2.5, 95% CI 1.4-4.5 and HR: 2.5, 95% CI
1.2-5.4, respectively), with women in the screen detected
category showing better outcomes compared to women
with symptomatic cancers (p=0.001 and p=0.007 for
recurrence and death, respectively). Age at diagnosis,
tumour size, nodal status and molecular subtypes were
also associated with survival outcomes (data available
upon request).
Regression models including exclusively molecular
subtypes showed a significant impact of mode of detec-
tion on the outcomes of interest (HR 2.26, 95% CI 1.26-
4.06; HR 2.24, 95% CI 1.06-4.73, for recurrence and
death, respectively). However, this result was not con-
firmed when further adjusting for age, tumour size and
nodal status (HR: 2.02, 95% CI 0.97-4.18 and HR: 2.68,
95% CI 0.92-7.77, for recurrence and death, respect-
ively). Age remained an independent prognostic factor
for death only (p=0.001), while nodal status had an im-
pact on both recurrence and death (p=0.0001). Data alsoshowed the molecular subtype role on disease recur-
rence (p= 0.0001) (Table 3).
In Table 4, tumour characteristics are reported by mo-
lecular subtypes. Among women with a luminal A sub-
type, screen detected cases were more commonly aged
50 or older, exhibited smaller tumours, and lower histo-
logical grade compared with symptomatic patients (74.3
vs. 67.4%, p=0.001; 87.0 vs. 55.4%, p=0.001 and 27.8 vs.
11.5%, p=0.006 for age at diagnosis, T≤2 cm and grade
1, respectively). In the luminal B subcategory, histo-
logical grade was significantly lower in screen detected
cases than in symptomatic cancers (77.8 vs. 35.6,
p=0.002). In the HER2+ subtype, lymph node involve-
ment was less common in screen detected cases than in
symptomatic patients (91.7 vs. 38.9, p=0.006).
In Figure 1, survival outcomes are shown by molecular
subtypes. In the luminal A subgroup, screen detected
cancers had significantly better outcomes than symp-
tomatic patients [91.8 vs. 77.8%, log rank=0.01 and 95.9
vs. 85.4%, log rank=0.02 for disease free survival (DFS)
and overall survival (OS), respectively].
We then tested variables to identify predictors of sur-
vival outcomes by applying Cox proportional hazard
models within strata of molecular subtypes (Table 5). In
the luminal A subtype, the multivariate analysis includ-
ing tumour size and nodal status confirmed the role of
mode of breast cancer detection in affecting cancer re-
currence (p=0.03), while estimates on survival were of
borderline significance (p=0.05). In this same subset of
patients, lymph node involvement significantly affected
both recurrence and death (p≤0.0001). In the HER2+
subtype, tumour size was an independent predictor of
recurrence (p=0.03). In triple negative cancers, tumour
size showed a significant impact on recurrence (p=0.03),
while nodal status influenced both recurrence and death
(p=0.001 and p=0.01, respectively).
Regression models showed no significant interaction
between mode of breast cancer detection and molecular
subtype for both the outcomes of interest (available
upon request).
Discussion
In the present study, we analyzed data from a clinical
series of 448 women with operable breast cancer and
compared characteristics related to patients tumour,
treatment, and outcomes by mode of breast cancer de-
tection. We observed more favourable prognostic factors
and survival outcomes in women with screen detected
breast cancers compared with symptomatic patients.
The independent role of mode of breast cancer detec-
tion was not confirmed in multivariate analyses includ-
ing age, tumour size and nodal status. However, adjusted
and unadjusted HR did not dramatically differ and the
two 95% CIs largely overlapped.
Table 2 Tumor characteristics, type of surgery, adjuvant
treatment and survival outcomes by mode of breast
cancer detection
MODE OF DETECTION
SYMPTOMATIC SCREEN
DETECTED
P-VALUE
TUMOR CHARACTERISTICS No. % No. %
TOTAL 334 74.5 114 25.5
Tumor size <.0001
T1 166 51.7 84 80.8
T2 123 38.3 19 18.3
T3–T4 32 10.0 1 1.0
No. of positive Lymph
nodes
.01
All lymph nodes negative 167 52.8 73 70.2
1–3 77 24.4 20 19.2
4–9 52 16.5 9 8.7
≥10 20 6.3 2 1.9
Histological grade <.0001
1 23 7.2 20 18.5
2 120 37.7 49 45.4
3 175 55.0 39 36.1
IMMUNOISTOCHEMICAL
CHARACTERISTICS
ER status .11
Positive 236 70.7 88 77.2
Negative 98 29.3 26 22.8
PR status .04
Positive 227 68.0 89 78.1
Negative 107 32.0 25 21.9
Ki-67 .02
≤20% 141 44.1 60 57.1
>20% 179 55.9 45 42.9
HER2 status .96
0, 1+ 227 70.1 76 70.4
2+ 46 14.2 16 14.8
3+ 51 15.7 16 14.8
Molecular Subtypes .04
Luminal A 193 59.0 74 68.5 .09
Luminal B 59 18.2 18 16.7 .71
Non-Luminal HER2+ 38 11.0 14 13.0 .79
No Basal-like 18 5.6 2 1.8 .01
Basal-like 16 4.9 0
TREATMENT
CHARACTERISTICS
Type of surgery .005
Conservative 242 74.7 88 88.0
Mastectomy 82 25.3 12 12.0
Adjuvant Therapy .04
Table 2 Tumor characteristics, type of surgery, adjuvant
treatment and survival outcomes by mode of breast
cancer detection (Continued)
None 36 11.8 15 13.6
Radiation only 64 21.1 37 33.6
Chemotherapy only 33 10.9 8 7.3
Radiation and
Chemotherapy
171 56.2 50 45.5
Hormone given 244 81.3 92 83.6 .23
OUTCOME
CHARACTERISTICS
Vital status <.0001
Alive, no evidence of
disease
226 69.7 100 88.4
Alive with this cancer 40 12.3 5 4.4
Dead, no evidence of
disease
4 1.2 0 -
Dead from this cancer 54 16.6 8 7.0
Recurrence type .001
None 230 71 100 88.5
Loco-Regional 18 5.6 3 2.7
Distant 76 23.5 10 8.8
Abbreviations: BC, breast cancer; Subtypes: Luminal A (ER+ and/or PR+)
and HER2-; Luminal B (ER+ and/or PR+) and HER2+; Non-Luminal HER2+
(ER- and PR-) and HER2+; Triple Negative (ER-, PR- and HER2-).
Abbreviations: BC, breast cancer.
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cancer biology in explaining the impact of mode of
breast cancer detection on survival outcomes, we re-
analyzed data within strata defined by molecular sub-
types. Overall, screen detected cancers tended to show
more favourable prognostic features across the various
molecular categories. However, screen detected cancers
showed significantly better disease free and overall sur-
vival compared to symptomatic tumours in the luminal
A subtype only. In this subcategory, the multivariate
analyses confirmed the independent role of mode of de-
tection on recurrence, while there was only a suggestion
for its role on death.
Breast cancers in the screen detected group tended to
be smaller, more often node negative and with lower
histological grade compared with tumours in the symp-
tomatic group. Patients in this group tended to be older.
Age at breast cancer diagnosis is an independent prog-
nostic factor, with younger age associated to having
more aggressive tumour behaviour [18]. Screen detected
tumours were more likely to express ER and/or PgR and
to show a lower Ki67 index. The more favourable clini-
copathological characteristics provide a rationale for the
more conservative surgical approach and less frequent
administration of adjuvant therapy in screen detected
tumours. These findings are consistent with the results
of previous studies [6,7].
Table 3 Cox multivariate analysis of disease-free
and overall survival
Recur HR
(95% CI)
P-value Death HR
(95% CI)
P-value
Mode of BC
Detection
Screen
Detection
1.00 1.00
Symptomatic 2.02
(0.97–4.18)
.059 2.68
(0.92–7.77)
.07
Age .21 .001
<40 1.00 1.00
40–49 0.72
(0.34–1.54)
.42 1.24
(0.32–4.93)
.71
50–69 1.19
(0.62–2.28)
.63 3.61
(1.09–11.99)
.04
≥70 1.44
(0.67–3.08)
.35 6.56
(1.83–23.47)
.004
Tumor size .12 .14
T1 1.00 1.00
T2 1.36
(0.87–2.15)
.23 1.58
(0.86–2.91)
.11
T3–T4 2.03
(1.01–4.06)
.04 2.32 (0.96–5.6) .06
No. of positive
Lymph nodes
<.0001 <.0001
All lymph
nodes negative
1.00 1.00
1–3 2.22
(1.28–3.84)
.004 1.66
(0.77–3.54)
.19
≥4 5.31
(3.15–8.96)
<.0001 6.09
(3.07–11.96)
<.0001
Molecular
Subtypes*
<.0001 .22
Luminal A 1.00 1.00
Luminal B 1.46
(0.86–2.47)
.21 1.04
(0.51–2.14)
.89
Non-Luminal
HER2+
1.80
(0.97–3.35)
.06 2.23
(1.07–4.67)
.03
Non Basal-like 1.75
(0.68–4.53)
.22 1.08
(0.25–4.67)
.91
Basal-like 4.72
(2.13–10.46)
<.0001 2.06 (0.6–7.05) .24
Abbreviations: BC, breast cancer; D-FS, disease-free survival; OS, overall
survival; HR, hazard ratio; * Molecular Subtypes: Luminal A (ER+ and/or PR+)
and HER2-; Luminal B (ER+ and/or PR+) and HER2+; Non-Luminal HER2+
(ER- and PR-) and HER2+; Triple Negative (ER-, PR- and HER2-: CK5+ Basal-like;
Non Basal-like).
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ter survival outcomes. The survival advantage conferred
by screening has been mostly attributed to stage shift, i.e.
the proportional shift toward earlier-stage cancer at pres-
entation. The latter is a reflection of screening-related
lead-time bias, which lengthens survival duration and
explains, at least partly, the observed improvement inoutcomes of patients with screen detected tumours [19-
22]. However, consistent evidence supports an independ-
ent prognostic role of screen detection after adjustment
for disease stage. Indeed, Dawson and colleagues com-
pared the effects of screen detection with symptomatic
diagnosis on survival after adjustment for the Nottinghan
Prognostic Index, a prognostic indicator based on tumour
size, grade and lymph node status. The authors concluded
that the shift in NPI accounted only for the fifty-six per
cent of the survival benefit associated with screen detec-
tion [23].
In our study, symptomatic breast cancer patients tended
to be significantly younger. Younger age at breast cancer
diagnosis is associated with more aggressive tumour be-
havior and might help interpret differences in outcomes
by mode of detection [24].
Based on pre-set inclusion criteria, inoperable breast
cancer cases were excluded from our analysis. We can-
not estimate their exact proportion and distribution
across the study groups. However, given the tendency of
screen detected tumours to show smaller size compared
to symptomatic cases, we may presume that inoperable
cancer were more represented among symptomatic
patients, thus eventually contributing to worse survival
outcomes in this subgroup.
Our results might help explain the role of tumour
biology in affecting differences in survival outcomes be-
tween women diagnosed with screen detected tumours
and symptomatic patients. Indeed, we observed a signifi-
cantly higher percentage of luminal A subtype among
women within the screen detected group compared to
patients with symptomatic tumours. Conversely, the triple
negative subtype was significantly more common among
symptomatic patients compared to women with screen
detected tumours. This is consistent with the results
reported by Kim et al. and Dawson et [23,25]. Molecular
subtypes are largely and consistently recognized as predic-
tors of recurrence and death [10-12]. Since the luminal A
subtype is usually associated with more favorable out-
comes, it is plausible that the significantly higher propor-
tion of this molecular subtype within the screen detected
group (compared with the symptomatic group) might ex-
plain at least in part the survival advantage observed in
women with a screen detected cancer [26-28].
When comparing tumour characteristics and outcomes
of interests between screen detected and symptomatic
cancers across categories defined on the basis of the mo-
lecular subtypes, the number of predictors of a more
favorable prognosis was remarkable in the luminal A sub-
type only. This was the only subtype associated with a
significant advantage in survival outcomes. These findings
might strengthen the evidence in supporting a selective
influence of early detection on survival in less aggres-
sive tumours, i.e. luminal A subtype. Conversely, doubts
Table 4 Tumor characteristics by molecular subtypes
Luminal A Luminal B Non-Luminal HER2+ Triple Negative
N = 267 N = 77 N = 52 N = 36*
SYMPTOMATIC SCREEN
DETECTED‡
p-value SYMPTOMATIC SCREEN
DETECTED
p-value SYMPTOMATIC SCREEN
DETECTED
p-value SYMPTOMATIC SCREEN
DETECTED
p-value
(N, %) (N, %) (N, %) (N, %) (N, %) (N, %) (N, %) (N, %)
Age .001 .05 .34 .31
<40 years 24 (12.4) 2 (2.7) 9 (15.3) 0 6 (15.8) 1 (7.1) 4 (11.8) 0
40–49 39 (20.2) 17 823) 16 (27.1) 2 (11.1) 9 (23.7) 6 (42.9) 11 (32.4) 0
50–69 93 (48.2) 51 (68.9) 25 (42.4) 14 (77.8) 18 (47.4) 7 (50) 12 (35.3) 2
≥70 37 (19.2) 4 (5.4) 9 (15.3) 2 (11.1) 5 (13.2) 0 7 (20.6) 0
Tumor size <.0001 .53 .11 .14
T1 103 (55.4) 60 (87) 32 (55.2) 11 (64.7) 16 (44.4) 9 (75) 10 (30.3) 2 (100)
T2 60 (32.3) 9 (13) 22 (37.9) 6 (35.3) 17 (47.2) 2 (16.7) 22 (66.7) 0
T3–T4 23 (12.4) 0 4 (6.9) 0 3 (8.3) 1 (8.3) 1 (3.0) 0
Lymph
nodes
.21 .22 0.06 .31
None 101 (54.3) 45 (66.2) 27 (47.4) 12 (66.7) 14 (38.9) 11 (91.7) 22 (64.7) 1 (50)
1–3 41 (22) 13 (19.1) 19 (33.3) 5 (27.8) 14 (38.9) 1 (8.3) 4 (11.8) 1 (50)
≥4 44 (23.7) 10 (14.7) 11 (19.3) 1 (5.6) 8 (22.2) 0 8 (23.5) 0
Histological
grade
.006 .002 .81 .81
1 21 (11.5) 20 (27.8) 1 (2.7) 0
2 88 (48.1) 29 (40.3) 21 (35.6) 14 (77.8) 8 (21.6) 3 (23.1) 1 (3) 0
3 74 (40.4) 23 (31.9) 38 (64.4) 4 (22.2) 28 (75.7) 10 (76.9) 32 (97) 2 (100)
Ki-67 .15 .11 .23 .72
≤20% 102 (54.8) 46 (64.8) 22 (37.3) 10 (55.6) 12 (33.3) 2 (16.7) 2 (6.1) 0
>20% 84 (45.2) 25 (35.2) 37 (62.7) 8 (44.4) 24 (66.7) 10 (83.3) 31 (93.9) 2 (100)
‡ MG: Mammography; *36 TN: 20 Non Basal-like, 16 Basal-like.
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Figure 1 Effect of method of detection on disease-free and overall survival according to the molecular subtypes. A disease-free and B overall
survival for luminal A subtype. C disease-free and D overall survival for luminal B subtype. E disease-free and F overall survival for HER2+ subtype.
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http://www.biomedcentral.com/1471-2407/13/15remain concerning the efficacy in the amelioration of sur-
vival outcomes for more aggressive tumours.
A limited number of studies have investigated the associ-
ation of interest so far. Kim and coauthors retrospectively
reviewed the clinical and pathologic data from 3,141
patients who underwent surgery for the treatment of inva-
sive breast cancer at the Samsung Medical Center. Consist-
ently with our results, the authors observed more favorable
prognostic survival outcomes in screened-detected breast
cancers compared with symptomatic cases (5-year OS:
99.7 vs. 96.5%, p=0.001 and DFS: 96.4 vs. 90.7, p<0.001).
Screen detection was independently associated with
improved OS and DFS after adjustment for covariates
(HR=0.32, p=0.0035; HR: 0.58, p=0.020, respectively) [25].
We have previously mentioned the analysis from Dawson
et al., including data from 1379 women with invasive
breast cancers. The authors identified distinct differences
in the molecular characteristics of screen-detected vs.
symptomatic breast cancers. However, only minimal at-
tenuation of the screen-detected survival advantage was
observed after adjustment for the expression of individualmolecular biomarkers or molecular subtype in multivariate
analysis. Indeed, the percentage of survival benefit attribu-
table to these factors was 3-10%, with more than 30% of
the effect remaining unexplained [23]. In a recent study by
Shito and coauthors, screen detection was an independent
predictor of favourable distant disease-free survival in
multivariate analysis including age, grade and tumour size.
According to the authors’ conclusions, differences in mo-
lecular subtypes of screen-detected vs. symptomatic breast
cancers accounted in part for the better outcome of
screen-detected cancers. However, the effect of molecular
subtype on the survival advantage conferred by screen de-
tection was not assessed in this analysis [29].
Our study has some limitations. We analyzed data
from a clinical series of 448 women with operable breast
cancer. The sample size limitations mostly reflect on the
non-Luminal A subgroups, which are particularly under-
represented among patients included in our analysis.
Our study might lack sufficient power to highlight the
impact of molecular determinants on survival outcomes
by detection mode in non-Luminal A patients. When
Table 5 Cox multivariate analysis of disease-free
and overall survival by molecular subtypes
Recur P-
value
Death P-
valueHR (95% CI) HR (95% CI)
Luminal A
Mode of BC Detection
Screen Detected 1.00 1.00
Symptomatic 2.73
(1.05–7.13)
.03 4.2
(0.97–18.16)
.05
Tumor size .91 .72
T1 1.00 1.00
T2 1.11
(0.56–2.2)
.73 1.19
(0.51–2.78)
.74
T3–T4 1.09
(0.42–2.87)
.81 0.69
(0.18–2.58)
.52
No. of positive Lymph
nodes
<.0001 <.0001
All lymph nodes
negative
1.00 1.00
1–3 1.9
(0.81–4.47)
.12 2.84
(0.89–9.05)
.07
≥4 6.27
(3.05–12.91)
<.0001 9.69
(3.57–26.26)
<.0001
Luminal B
Mode of BC Detection
Screen Detected 1.00 1.00
Symptomatic 2.66 (0.59–
11.88)
.21 2.79 (0.33–
23.7)
.33
Tumor size .4 .05
T1 1.00 1.00
T2 1.05
(0.39–2.77)
.91 0.56
(0.11–2.92)
.53
T3–T4 2.61
(0.58–11.71)
.22 5.59
(1.03–30.22)
.04
No. of positive Lymph
nodes
.12 .74
All lymph nodes
negative
1.00 1.00
1–3 2.55
(0.82–7.88)
.01 0.81
(0.14–4.52)
.81
≥4 3.55
(1.02–12.42)
.04 1.66
(0.35–7.75)
.52
Non Luminal Her2+
Mode of BC Detection
Screen Detected 1.00 1.00
Symptomatic 1.86
(0.19–18.18)
.72 1.43
(0.14–14.05)
.91
Tumor size .03 .09
T1 1.00 1.00
T2 1.77
(0.47–6.67)
.44 5.48
(1.02–29.2)
.05
T3–T4 .01 .04
Table 5 Cox multivariate analysis of disease-free
and overall survival by molecular subtypes (Continued)
8.62
(1.65–44.78)
8.56
(1.05–69.9)
No. of positive Lymph
nodes
.81 .42
All lymph nodes
negative
1.00 1.00
1–3 1.47
(0.38–5.6)
.84 0.41
(0.09–1.88)
.22
≥4 1.54
(0.34–7.05)
.51 1.07
(0.22–5.1)
.91
Triple Negative
Mode of BC Detection
Screen Detected 1.00 1.00
Symptomatic 0.14
(0.008–2.39)
.11 n.e*.
Tumor size .11 .12
T1 1.00 1.00
≥T2 7.17
(1.15–44.72)
.03 7.41
(0.61–89.8)
.14
No. of positive Lymph
nodes
.001 .01
All lymph nodes
negative
1.00 1.00
All lymph nodes
positive
3.58
(3.65–7.76)
.001 4.85
(1.46–16.13)
.01
*n.e. not evaluable.
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http://www.biomedcentral.com/1471-2407/13/15assessing the interaction between mode of breast cancer
and molecular subtypes for the outcomes of interest, we
observed non significant results. However, interaction
effects are often undetectable in subgroup analyses when
sufficient power is lacking [30]. The relatively limited
sample size and study design, i.e., clinical series, both
concur to limit the ability to make definitive interpretation
of this data and encourage conducting further research
based on specifically conceived, adequately powered, pro-
spective studies.
Mode of breast cancer detection was defined on the basis
of self reported data. The remarkably low percentage of
women having undertaken mammography within an orga-
nized screening program discouraged us from relying on
official records to confirm our data. Under these circum-
stances, misclassification bias cannot be excluded. However,
evidence from a validation study of self reported screening
mammography histories suggests that non differential ra-
ther than differential is a more likely type of error and that
the related estimates might understate the effects of screen-
ing detection regarding breast cancer outcomes [31].
Our study also has several strengths. Data on demo-
graphics and mode of breast cancer detection were
collected using a specifically conceived questionnaire
Crispo et al. BMC Cancer 2013, 13:15 Page 10 of 11
http://www.biomedcentral.com/1471-2407/13/15which was administered during face-to face interviews.
Abstraction of medical records on (breast cancer) patho-
logic features, treatment and outcomes was carried out
by a specifically trained medical assistant who worked
in close collaboration with the oncologists who had pro-
spectively followed the patients included in our ana-
lyses. This increases our confidence in the quality of the
data collected.
In our analyses, we included data concerning a wide
panel of molecular biomarkers. In particular, we were
able to gather data on biomarkers such as Ki-67, CK 5/6,
CK14 and EGFR which were not available in previous
studies [25].
Conclusions
In conclusions, breast cancer patients with mammog-
raphy detected tumours tended to show more favourable
clinicopathological features and survival outcomes com-
pared to women who were symptomatic at cancer diag-
nosis. Patients with screen detected breast cancers were
more likely to exhibit a luminal A subtype.
This is associated with better survival outcomes and
might per se explain at least a proportion of the advan-
tage in survival observed in mammography detected
cancers. Data analysis across categories of molecular
subtypes revealed significantly longer disease free and
overall survival for screen detected cancers with a lu-
minal A subtype only. In the luminal A subtype, the in-
dependent prognostic role of mode of breast cancer
detection on cancer recurrence was confirmed in Cox
proportional hazard models. These same models also
suggested an independent prognostic role of modality of
detection on survival.
Overall, molecular subtypes did not substantially ex-
plain differences in survival outcomes between screened
and symptomatic patients. However, our results suggest
that molecular profiles might play a role in interpreting
such differences at least partially. If this is confirmed,
the efficacy of screening programmes would be revisited
in light of tumour biology.
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